Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Probiotics01:22

Probiotics

296
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
296
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Liver Physiology01:30

Liver Physiology

3.8K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel laccases for synthetic dye pollution mitigation-screening, statistical optimization and molecular characterization.

3 Biotech·2026
Same author

Genotyping and molecular dynamic simulations reveal the role of MSH2 DNA repair polymorphisms in lung cancer risk.

Journal of biomolecular structure & dynamics·2025
Same author

Modeling hexavalent chromium removal from aqueous systems using a fixed bed of immobilized bacteria and zero-valent iron nanoparticles.

3 Biotech·2025
Same author

Identification of non-synonymous SNPs affecting structure and function of MLH1 and NBN proteins: a computational approach.

Journal of applied genetics·2025
Same author

Statistical optimization of process variables for improved poly(ethylene terephthalate) plastic degradation by a rhizospheric bacterial consortium.

Scientific reports·2025
Same author

Equilibrium and kinetic modeling of Cr(VI) removal by novel tolerant bacteria species along with zero-valent iron nanoparticles.

Scientific reports·2024

Related Experiment Video

Updated: May 4, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.7K

Probiotics and liver disease.

Vishal Sharma1, Shashank Garg2, Sourabh Aggarwal3

  • 1Senior Research Associate at the Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. docvishalsharma@gmail.com.

The Permanente Journal
|December 24, 2013
PubMed
Summary

Changes in gut bacteria impact liver health via the gut-liver axis. Probiotics, prebiotics, and synbiotics may help manage liver disorders by modulating gut microbiota and reducing harmful interactions.

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

13.0K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.1K

Related Experiment Videos

Last Updated: May 4, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.7K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

13.0K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.1K

Area of Science:

  • Microbiology
  • Hepatology
  • Gastroenterology

Background:

  • The gut-liver axis describes the bidirectional communication between the intestines and the liver.
  • Bacterial products, such as lipopolysaccharide, interact with hepatic receptors (Toll-like receptors), influencing liver health.
  • Intestinal dysbiosis and increased intestinal permeability can disrupt this axis, contributing to liver disease development or exacerbation.

Purpose of the Study:

  • To review the alterations in gut microbiota composition associated with liver disease.
  • To explore the potential therapeutic roles of probiotics, prebiotics, and synbiotics in managing liver disorders.

Main Methods:

  • Literature review focusing on studies examining gut microbiota in liver disease.
  • Analysis of research on the mechanisms of the gut-liver axis.
  • Evaluation of evidence for the efficacy of probiotics, prebiotics, and synbiotics in liver disease models and human studies.

Main Results:

  • Liver diseases are frequently associated with significant changes in the composition and function of the intestinal microbiota (dysbiosis).
  • Altered gut permeability allows bacterial components to translocate to the liver, promoting inflammation and liver damage.
  • Emerging evidence suggests that interventions like probiotics, prebiotics, and synbiotics can positively modulate the gut microbiota and ameliorate liver disease progression.

Conclusions:

  • Gut microbiota dysbiosis is a key factor in the pathogenesis and progression of various liver disorders.
  • Modulating the gut microbiota through probiotics, prebiotics, and synbiotics presents a promising therapeutic strategy for liver disease.
  • Further research is warranted to optimize these interventions for clinical application in hepatology.